Drugs / EPREX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03276910 | Sep → Dec 2017 | substance abuse | Association Athletes For Transparency | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPREX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03276910 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human erythropoietin” NCT03276910 ↗ |
| Route | Subcutaneous | “6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use” NCT03276910 ↗ |